Concerns on Bebtelovimab (LY-CoV1404) used to neutralize Omicron subvariants

J Med Virol. 2023 Feb;95(2):e28565. doi: 10.1002/jmv.28565.

Authors

Xuejun Wang¹, Yang Yang^{1

2}, Zhifei Song¹, Yiming Wang^{1

3}, Peng Yang^{1

2}, Xinyu Li¹, Fei Wang^{1

2}, Mingming Wang¹, Liting Shao¹, Shengqi Wang¹

Affiliations

¹ State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
² Youcare Pharmaceutical Group Co., Ltd., Beijing, China.
³ College of Life Sciences, Henan Normal University, Xinxiang, China.

PMID: 36756927
DOI: 10.1002/jmv.28565

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Neutralizing*
Humans
SARS-CoV-2* / drug effects

Substances

Antibodies, Neutralizing

Supplementary concepts

SARS-CoV-2 variants